CellSource Co

CellSource Co Equity Ratio

The Equity Ratio of CellSource Co (4880.T) as of Oct 31, 2026 is 84.59 %. In the previous year, Equity Ratio was 84.22 % — a change of 0.44% (higher).

Equity Ratio

84.59 %

YoY

0.44%

Last updated:

Equity Ratio of CellSource Co is 2025 84.59 % . Equity Ratio of CellSource Co was 2024 84.22 % . It decreases by 0.44% higher compared to the previous year.

The CellSource Co Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
57.57 JPY
Jan 1, 2019
86.83 JPY
Jan 1, 2020
86.84 JPY
Jan 1, 2021
80.82 JPY
Jan 1, 2022
82.27 JPY
Jan 1, 2023
90.00 JPY
Jan 1, 2024
84.22 JPY
Jan 1, 2025
84.59 JPY
The CellSource Co Equity Ratio history
YEAREquity RatioYoY
84.59 %+0.44%
84.22 %-6.42%
90.00 %+9.39%
82.27 %+1.80%
80.82 %-6.93%
86.84 %+0.00%
86.83 %+50.84%
57.57 %-9.32%
63.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Equity Ratio of CellSource Co is 84.59 % in 2025.

Equity Ratio of CellSource Co changed from 84.22 % to 84.59 %, representing a 0.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio CellSource Co since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's CellSource Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — CellSource Co

All Key Metrics — CellSource Co